Natixis Advisors, L.P. Charles River Laboratories International, Inc. Transaction History

Natixis Advisors, L.P.

$51.3 Billion
Q3 2024

A detailed history of Natixis Advisors, L.P. transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 84,143 shares of CRL stock, worth $15.7 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

84,143

Previous 88,453 4.87%

Holding current value

$15.7 Million

Previous $18.3 Million 9.3%

% of portfolio

0.03%

Previous 0.04%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$187.96 - $245.29 $810,107 - $1.06 Million	-4,310 Reduced 4.87%	84,143 $16.6 Million
Q2 2024 Aug 01, 2024	BUY	$206.39 - $268.73 $1.99 Million - $2.6 Million	9,664 Added 12.27%	88,453 $18.3 Million
Q1 2024 Apr 25, 2024	BUY	$203.52 - $273.43 $2.43 Million - $3.26 Million	11,934 Added 17.85%	78,789 $21.3 Million
Q4 2023 Feb 06, 2024	BUY	$164.52 - $238.84 $1.14 Million - $1.65 Million	6,913 Added 11.53%	66,855 $15.8 Million
Q3 2023 Nov 13, 2023	BUY	$194.44 - $217.61 $1.73 Million - $1.94 Million	8,903 Added 17.44%	59,942 $11.7 Million
Q2 2023 Aug 15, 2023	BUY	$183.71 - $210.25 $2.5 Million - $2.86 Million	13,592 Added 36.3%	51,039 $10.7 Million
Q1 2023 May 11, 2023	BUY	$191.89 - $259.92 $578,932 - $784,178	3,017 Added 8.76%	37,447 $7.56 Million
Q4 2022 Jan 27, 2023	BUY	$197.11 - $250.07 $885,615 - $1.12 Million	4,493 Added 15.01%	34,430 $7.5 Million
Q3 2022 Nov 14, 2022	BUY	$182.44 - $250.54 $360,136 - $494,565	1,974 Added 7.06%	29,937 $5.89 Million
Q2 2022 Aug 12, 2022	BUY	$204.13 - $302.4 $243,527 - $360,763	1,193 Added 4.46%	27,963 $5.98 Million
Q1 2022 May 12, 2022	BUY	$255.51 - $362.11 $1.28 Million - $1.81 Million	5,007 Added 23.01%	26,770 $7.6 Million
Q4 2021 Feb 08, 2022	SELL	$351.38 - $448.68 $754,412 - $963,315	-2,147 Reduced 8.98%	21,763 $8.2 Million
Q3 2021 Nov 15, 2021	SELL	$372.64 - $458.3 $842,911 - $1.04 Million	-2,262 Reduced 8.64%	23,910 $9.87 Million
Q2 2021 Aug 12, 2021	BUY	$294.17 - $371.65 $136,789 - $172,817	465 Added 1.81%	26,172 $9.68 Million
Q1 2021 May 05, 2021	SELL	$249.67 - $299.48 $39,947 - $47,916	-160 Reduced 0.62%	25,707 $7.45 Million
Q4 2020 Feb 12, 2021	SELL	$222.0 - $252.62 $3.42 Million - $3.89 Million	-15,392 Reduced 37.31%	25,867 $6.46 Million
Q3 2020 Nov 12, 2020	SELL	$175.56 - $226.45 $559,158 - $721,243	-3,185 Reduced 7.17%	41,259 $9.34 Million
Q2 2020 Aug 11, 2020	SELL	$118.84 - $189.72 $231,738 - $369,954	-1,950 Reduced 4.2%	44,444 $7.75 Million
Q1 2020 Apr 27, 2020	BUY	$98.9 - $178.34 $1.05 Million - $1.89 Million	10,576 Added 29.53%	46,394 $5.86 Million
Q4 2019 Feb 10, 2020	BUY	$126.05 - $152.76 $598,485 - $725,304	4,748 Added 15.28%	35,818 $5.47 Million
Q3 2019 Nov 12, 2019	BUY	$125.07 - $143.67 $929,770 - $1.07 Million	7,434 Added 31.45%	31,070 $4.11 Million
Q2 2019 Aug 12, 2019	SELL	$123.4 - $148.55 $2,838 - $3,416	-23 Reduced 0.1%	23,636 $3.35 Million
Q1 2019 May 15, 2019	BUY	$104.82 - $146.73 $64,569 - $90,385	616 Added 2.67%	23,659 $3.44 Million
Q4 2018 Feb 13, 2019	BUY	$105.09 - $137.23 $162,153 - $211,745	1,543 Added 7.18%	23,043 $2.61 Million
Q3 2018 Nov 13, 2018	BUY	$112.11 - $134.54 $106,168 - $127,409	947 Added 4.61%	21,500 $2.89 Million
Q2 2018 Aug 14, 2018	BUY	$102.37 - $117.25 $247,121 - $283,041	2,414 Added 13.31%	20,553 $0
Q1 2018 May 10, 2018	BUY	$98.19 - $115.2 $190,783 - $223,833	1,943 Added 12.0%	18,139 $1.94 Million
Q4 2017 Feb 14, 2018	BUY	$100.43 - $118.09 $137,187 - $161,310	1,366 Added 9.21%	16,196 $1.77 Million
Q3 2017 Nov 14, 2017	BUY	$96.72 - $109.26 $1.43 Million - $1.62 Million	14,830	14,830 $1.6 Million

Others Institutions Holding CRL

# of Institutions

696

Shares Held

52.2M

Call Options Held

259K

Put Options Held

463K

View Full List

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Ticker CRL
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 50,863,300
Market Cap $9.47B
Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...

More about CRL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Charles River Laboratories International, Inc. Transaction History